FLX475

DRUG3 trials

Sponsors

Hanmi Pharmaceutical Company Limited, RAPT Therapeutics, Inc., FLX Bio, Inc. PRA Health Sciences located at Van Swietenlaan 6, 9728 NZ Groningen, in The Netherlands.

Conditions

Advanced MelanomaGastric CancerHealthy human volunteers (preliminary safety study) Cancer

Phase 2

FLX475 Combined With Pembrolizumab in Patients With Advanced or Metastatic Gastric Cancer

CompletedNCT04768686

Hanmi Pharmaceutical Company LimitedGastric Cancer

Start: 2021-05-18End: 2024-08-12Updated: 2025-09-25

FLX475 in Combination With Ipilimumab in Advanced Melanoma

TerminatedNCT04894994

RAPT Therapeutics, Inc.Advanced Melanoma

Start: 2021-09-03End: 2022-09-13Updated: 2023-12-05

Unknown Phase

A First-in-Human Study of FLX475 in Healthy Volunteers

RecruitingNL-OMON26146

FLX Bio, Inc. PRA Health Sciences located at Van Swietenlaan 6, 9728 NZ Groningen, in The Netherlands.Healthy human volunteers (preliminary safety study) Cancer

Start: 2017-11-17Target: 104Updated: 2024-02-28

Related Papers

A phase 2 study to assess the safety and efficacy of FLX475 (tivumecirnon) combined with pembrolizumab in patients with advanced or metastatic gastric cancer.

Journal of Clinical Oncology2025-01-27

658 A phase 2 study to assess the safety, efficacy of FLX475 combined with pembrolizumab in patients with advanced or metastatic gastric cancer

Regular and Young Investigator Award Abstracts2022-11-012 citations

409 Trial in progress: a phase 2 study to assess the safety, efficacy of FLX475 combined with pembrolizumab in patients with advanced or metastatic gastric cancer

Regular and Young Investigator Award Abstracts2021-11-013 citations

548 Phase 2 study of FLX475 in combination with ipilimumab in advanced melanoma

Regular and Young Investigator Award Abstracts2021-11-011 citations